The rare and age-related disease-focused startup emerged from a drug discovery collaboration between Evotec and Apollo Health Ventures, both of which chipped into the round.

US-based rare and age-related disease therapy developer Aeovian Pharmaceuticals has completed a $37m series A financing round that included drug discovery services provider Evotec. Life sciences-focused investment firms Sofinnova Investments and VenBio Partners co-led the round, which also featured geroscience-focused venture capital firm Apollo Health Ventures. Founded to exploit research conducted at Buck Institute of…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.